Effects of Allogeneic Blood Transfusion in Patients with Stage II Colon Cancer

Abstract

The aim of the present study was to determine whether allogeneic red blood cell transfusions showed a deleterious effect and what might be preoperative risk factors for blood transfusion in patients with TNM stage II colon cancer. Total 470 patients who fulfilled inclusion criteria were selected for a further 10-year followup study. We found that there were statistical significance between non-transfused and transfused group in mortality (P=0.018), local recurrence (P=0.000) and distant metastasis (P=0.040). Local recurrence and distant metastasis between 1 to 3 units and more than 3 units group did not show any significant differences. There was no difference in survival rate between non-transfused and 1 to 3 units group (log rank =0.031, P=0.860). The difference between different blood transfusion volume in transfused patients was found (78.77% vs 63.83%, P=0.006). Meanwhile, the significant difference of survival rate was existed between non-transfused group and more than 3 units group (84.83% vs 63.83%, P=0.002 ). Univariate analysis showed the following 3 variables to be associated with an increased risk of allogeneic blood transfusions: preoperative CEA level (P<0.05), location of tumor (P<0.01) and diameter of tumor (P<0.01). Multivariate analysis revealed that location of tumor and diameter of tumor are two independent factors for requirement of perioperative transfusions. Therefore, allogeneic transfusion increase the postoperative tumor mortality, local recurrence and distant metastasis in patients with stage II colon cancer. The postoperative tumor mortality, local recurrence and distant metastasis were not associated with the blood transfusion volume. The blood transfusion volume was associated with the survival rate. Location of tumor and diameter of tumor were the independent preoperative risk factors for blood transfusion.

Clinical Practice of Blood Transfusion in Orthotopic Organ Transplantation: A Single Institution Experience

“…Recent studies had demonstrated that peri-operative allogeneic blood transfusion had an adverse effect on patients with surgical intervention in various malignancies (Liu et al, 2013;Meng et al, 2013;Ramos et al, 2003;Sugita et al, 2008;Wang et al, 2015). Some of these investigations further indicated that peri-operative transfusion of RBC product, rather than post-operative, was highly associated with prolonged hospital stay as well as increased morbidity and mortality (Ramos et al, 2003;Sugita et al, 2008).…”

Influence of Autologous and Homologous Blood Transfusion on Interleukins and Tumor Necrosis Factor-α in Peri-operative Patients with Esophageal Cancer

“…In addition, intra-operative blood transfusion is an indispensible complementary therapy due to the large traumas, longer duration and more hemorrhage volume in the operations for cancer patients, which can immediately remedy the intraoperative anemia and insufficient blood volume. However, blood transfusion-associated immunosuppression may further aggravate the postoperative immunosuppression of cancer patients, which will enable residual and exfoliative tumor cells escape from immunological surveillance, leading to recurrence and distant metastasis of tumors (De Oliveira et al, 2012;Meng et al, 2013). A study found that autologous blood transfusion could improve the postoperative immunological function and protect organs of cancer patients (Han et al, 2011;Stachura et al, 2011).…”

Use of Blood Transfusion at the End of Life: Does it Have Any Effects on Survival of Cancer Patients?

“…However, there is evidence in the literature that blood transfusion may have a negative impact on the progression of disease. Meng J had demonstreated that allogeneic blood transfusion increased the postoperative tumor mortality, local recurrence and distant metastasis in patients with colon cancer ( Meng et al, 2013).…”